Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | CHUK | O15111 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.35 |
| ▸ | LHCGR | P22888 | 1/20 | 0.35 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.32 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.32 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.32 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2565245 | 0.89 | HSP90AB1 (0.41) | CHUKHSP90AB1 | |
| SCHEMBL13798696 | 0.83 | HSP90AB1 (0.40) | HSP90AB1ADORA2AADORA1 | |
| SCHEMBL2567605 | 0.80 | HSP90AB1 (0.52) | HSP90AB1PDE10A | |
| SCHEMBL13798694 | 0.78 | HSP90AB1 (0.54) | HSP90AB1 | |
| SCHEMBL3561868 | 0.78 | LRRK2 (0.46) | CYP19A1AR | |
| SCHEMBL2562784 | 0.78 | CYP1A2 (0.33) | HSP90AB1 | |
| SCHEMBL2564812 | 0.77 | KLKB1 (0.32) | — | |
| SCHEMBL2568420 | 0.77 | HSP90AB1 (0.47) | HSP90AB1 | |
| SCHEMBL2566599 | 0.76 | KCNH2 (0.43) | HSP90AB1 | |
| SCHEMBL2565058 | 0.76 | HSP90AB1 (0.46) | HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | VERNALIS (R&D) LTD. (GB) | 2009-06-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090163490-A1 | Pyrrolopyrimidine Derivatives Used As HSP90 Inhibitors | HSP90AA1, HSP90AB1, RAF1 | IKBKB 756/4885CHUK 258/4885HSP90AB1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.